Thera-SAbDab

BENRALIZUMAB

> Structural Summary

Therapeutic	Benralizumab
Target	IL5RA
Heavy Chain	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	Active
Recorded Developmental Technology	POTELLIGENT Technology
INN Year Proposed	2009
INN Year Recommended	2010
Companies Involved	AstraZeneca, Cincinnati Children's Hospital Medical Center, Kyowa Hakko, Kyowa Hakko Kirin, McMaster University, MedImmune, National Jewish Medical and Research Center, BioWa
Conditions Approved	Asthma
Conditions Active	Chronic obstructive pulmonary disease, Nasal polyps, Atopic dermatitis, Churg-Strauss syndrome, Hypereosinophilic syndrome, Rhinosinusitis, Eosinophilic gastroenteritis, Skin disorders
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]